Volume 14, Number 11—November 2008
Research
Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
, and for the German TBNET Group
Table 1
Demographic and clinical characteristics of 184 patients with MDR TB and XDR TB, Germany*
| Variables | MDR TB, n = 177 | XDR TB, n = 7 | p value | 95% CI |
|---|---|---|---|---|
| Male gender, no. (%) | 133 (75.1) | 6 (85.7) | 0.54 | –0.37 to 0.17 |
| Age, y, mean ± SD |
37.7 ± 15.4 |
42.4 ± 11.9 |
0.42 |
–16.33 to 6.93 |
| Country of birth, no. (%) | ||||
| Former Soviet Union | 142 (80.2) | 6 (85.7) | 0.74 | –0.32 to 0.22 |
| Germany | 11 (6.2) | – | – | – |
| Others |
24 (13.6) |
1 (14.3) |
0.93 |
–0.27 to 0.25 |
| HIV positive, no. (%) |
7/142 (4.9) |
0 |
0.54 |
0.01 to 0.08 |
| Kind of TB, no. (%) | ||||
| Pulmonary TB | 162 (91.5) | 6 (85.7) | 0.59 | –0.2 to 0.32 |
| Extrapulmonary TB | 5 (2.9) | – | – | – |
| Pulmonary and extrapulmonary TB |
10 (5.6) |
1 (14.3) |
0.29 |
–0.34 to 0.16 |
| Days in hospital, mean ± SD | 123.3 ± 81 | 202 ± 130 | 0.015† | –141.8 to –15.53 |
| Previous TB treatment, no. (%) | 94 (53) | 6 (86) | 0.08 | –0.59 to 0.06 |
| Resistance to all first-line drugs, no. (%) | 64 (36) | 6 (85.7) | 0.008 | –0.76 to –0.21 |
| Resistance to fluoroquinolones, no. (%) | 13/162 (8) | 7 (100) | <0.001† | –0.96 to –0.87 |
| Resistance to injectable second-line drugs, no. (%) | 21/164 (12.8) | 7 (100) | <0.001† | –0.92 to –0.83 |
| Linezolid treatment, no. (%) |
69 (39) |
5 (71.4) |
0.09 |
–0.66 to 0.02 |
| Treatment outcome, no. (%) | ||||
| Cured | 79 (44.6) | 3 (42.8) | 0.91 | –0.35 to 0.39 |
| Completed | 26 (14.7) | 1 (14.3) | 1 | –0.26 to 0.26 |
| Successful treatment (cured + completed) | 105 (59.3) | 4 (57.1) | 0.91 | –0.35 to 0.39 |
| Died | 14 (7.9) | 1 (14.3) | 0.4 | –0.32 to 0.18 |
| Failure | 1 (0.6) | – | – | – |
| Treatment failure (death or failure) | 15 (8.4) | 1 (14.3) | 0.57 | –0.32 to 0.2 |
| Default | 1 (0.6) | – | – | – |
| Transferred out | 25 (14.1) | – | – | – |
| Uncertain outcome (default + transferred out) | 26 (14.7) | – | – | – |
| Still on treatment |
31 (17.5) |
2 (28.6) |
0.45 |
–0.44 to 0.22 |
| Duration of therapy from beginning MDR treatment, mo, mean ± SD |
18 ± 9 |
20 ± 5 |
0.56 |
–8.78 to 4.78 |
| Sputum smear conversion, no. (%) | 98 (55.4) | 5 (71.4) | 0.4 | –0.5 to 0.18 |
| Culture conversion, no. (%) | 132 (74.6) | 5 (71.4) | 0.85 | –0.31 to 0.37 |
| Sputum smear conversion, d, mean ± SD | 69.4 ± 76 | 129.8 ± 129.2 | 0.09 | –132 to 11.2 |
| Culture conversion, d, mean ± SD | 81.3 ± 74.6 | 141 ± 99.7 | 0.08 | –127.6 to 8.2 |
*MDR, multidrug-resistant; TB, tuberculosis; XDR, extensively drug-resistant; CI, confidence interval.
†Significant result (p<0.05).
1Additional German Tuberculosis Network European Trials group (TBNET) contributors: R. Eberhardt, Thorax-Clinic-Heidelberg, Heidelberg; A. Esselmann, Pulmonary Clinic, Hemer; H. Flick, Charité, Berlin; M. Hamm, Hospital Diekholzen, Diekholzen; P. Hammerl, Hospital Immenhausen, Immenhausen; H. Hang, Hospital Schillerhöhe, Schillerhöhe; P. Hannemann, Deakoness Hospital, Neustadt; D. Hillemann, Research Center Borstel, Borstel; B. Kretz, Asklepios Hospital, Gauting; C. Laumanns, Bethania Hospital, Solingen; G. Liebetrau, Lostau Hospital, Lostau; S. Ott, Helios Clinic Emil von Behring, Berlin; A. Paulick, Pulmonary Clinic-Coswig, Coswig; M.W. Pletz, Hannover Medical School, Hannover; M. Rau, Pulmonary Clinic, Wangen; G. Rohde, Bergmannsheil Hospital, Bochum; A. de Roux, Evangelische Lungenklinik, Berlin; C. Schaudt, Hospital St. Blasien, St. Blasien; K-D.Schneider, Pulmonary Clinic, Hannover-East, Hannover; S. Stenger, University Hospital, Ulm; D. Wagner, University Hospital, Freiburg; and T. Wolf, University Hospital, Frankfurt.